Novel Gene Therapy Drug for Huntington's Disease

ITHACA, N.Y., Aug. 24, 2016 /PRNewswire/ -- Data from Vybion on a novel treatment for Huntington's disease has been published in the Journal of Neurodegenerative diseases. The published study (http://www.hindawi.com/journals/jnd/2016/7120753/) links the ability of Vybion's proprietary, novel Intrabody (INT41) blocking of cellular gene dysregulation to the delay of cognitive and motor function loss in the well-validated vR6/2 animal model.

INT41 interferes with direct binding of toxic N-terminal huntingtin fragments to DNA, as well as their transport into the nucleus. The data support a direct gain of function of N-terminal huntingtin protein fragments that may lead to neuron dysfunction and brain atrophy as well as a novel therapeutic modality. The data also demonstrate that Vybion's platform may have broader application in generating Intrabody drug candidates to difficult-to-drug targets, including intracellular proteins in neurodegenerative disorders and other disease areas such as oncology. Further, the platform may be used to validate new targets of interest, particularly in intracellular signal transduction pathways, prior to generation of new therapeutic candidates.

"We believe that our therapeutic approach to the treatment of Huntington's disease has provided a biological rationale linking Huntington's disease progression and toxic N-terminal fragments. We look forward to completing our plans for human patient trials," says Lee Henderson, PhD, CEO of Vybion. 

About Vybion: Vybion, Inc. is a development stage Company with proprietary technologies for Intrabody discovery and development to treat neurodegenerative diseases such as Huntington's, SBMA and SCA1, 3 and 7.  The Company is currently in late pre-clinical development with INT41 in Huntington's Disease. The Intrabody platform is applicable to target validation in intracellular signal transduction pathways and can be applied to multiple therapeutic areas.

About Inverness: Inverness Advisors LLC, based in San Francisco and a division of KEMA Partners LLC, is an investment bank that provides capital raising and mergers & acquisitions advisory services to clients in the technology, media and healthcare industries. Inverness Advisors conducts all securities business through KEMA Partners LLC, a FINRA member and SEC-registered broker-dealer.

Contacts:
Lee A. Henderson, Ph.D.
[email protected]

David Raksin, 
[email protected] 
415-813-6107

SOURCE Vybion, Inc.

Related Links

http://www.vybion.com